Abstract: The semiconductor device includes a first semiconductor component including a first circuit section and an interconnection connected to the first circuit section, and a second semiconductor component including a second circuit section and a third circuit section and stacked on the first semiconductor component. The interconnection is electrically connected to a first connecting portion and a second connecting portion of a plurality of connecting portions for electrically connecting the first semiconductor component and the second semiconductor component. The second circuit section is electrically connected to the interconnection via the first connecting portion. The third circuit section is electrically connected to the interconnection via the second connecting portion.

Abstract: One embodiment is a printing apparatus comprising: a conveyance unit configured to convey a printing medium in a conveyance direction; and a printing head configured to eject a liquid, and being capable of conducting a maintenance control on the printing head while temporarily pausing a printing operation and configured to execute tiled printing of printing an image in which a plurality of printed products obtained by printing are assumed to be arranged adjacent to each other, while dividing the image into a plurality of pages including at least a first page and a second page, wherein the printing apparatus is configured to control whether or not to conduct the maintenance control based on a conveyance-direction distance from a top of the page along the conveyance direction for the page during printing in a case of executing the tiled printing and printing each of the plurality of pages.

Abstract: In order to provide a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to neutralize SARS-CoV-2, an antigen-binding fragment thereof, and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, the present invention provides: a human-derived monoclonal antibody against SARS-CoV-2, the antibody binding to the S protein of SARS-CoV-2 to neutralize viral activity of the S protein including an immune escape mutation; an antigen-binding fragment thereof; nucleic acids encoding the antibody and the antigen-binding fragment thereof; and a pharmaceutical composition for treating or preventing a SARS-CoV-2 coronavirus infectious disease, the pharmaceutical composition containing the antibody or the antigen-binding fragment thereof.

Abstract: A terminal according to one aspect of the present disclosure includes a receiving section that receives a configuration indicating that disabling or enabling of a transform precoder for a physical downlink shared channel (PUSCH) is dynamically switched by at least one of downlink control information (DCI) and a Medium Access Control Control Element (MAC CE), and a control section that uses, as a period from reception of the DCI until transmission of the PUSCH, a second period longer than a first period in a case where the waveform is not switched. According to one aspect of the present disclosure, it is possible to easily perform switching of a waveform.

Abstract: A printing apparatus includes a feed unit that feeds a printing medium; a print unit including first and second arrays of print elements for applying first ink and second ink, respectively, onto the printing medium; and a fixation unit located downstream of the print unit in a feed direction to fixate an image printed on the printing medium. The print unit prints a first image on the printing medium by applying the first ink. The feed unit feeds the printing medium having the first image printed thereon to the fixation unit from upstream to downstream in the feed direction. The fixation unit fixates the first image. The feed unit back-feeds the printing medium having the first image fixated thereon to the print unit from downstream to upstream in the feed direction. The print unit prints a second image on the first image by applying the second ink.

Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.

Abstract: Provided is a method for producing a coating film formed on the skin by electrostatic spraying, the coating film having good feeling and not causing damage on the coating film even after a lapse of a long time A method for producing a coating film on the skin, comprising the steps of: A) electrostatically spraying a composition X comprising a component (a) and a component (b) directly onto the skin to form a coating film on a surface of the skin: (a) one or more volatile substances selected from the group consisting of water, an alcohol and a ketone; (b) a polymer capable of forming a coating film; and B) applying a composition Y other than the composition X, comprising a component (c) and a component (d) to the skin in the order presented or in reverse order: (c) 0.5% by mass or more and less than 5% by mass of an adhesive polymer; (d) one or more selected from the group consisting of a polyol and a liquid oil.

Abstract: An in-vehicle electronic system is mounted to a vehicle. The in-vehicle electronic system includes one or more sensors used to determine a security state of the vehicle, an alarm apparatus configured to issue an alarm when the security state is abnormal, and a first ECU directly connected to the sensor and the alarm apparatus without the intermediation of another ECU and also connected to a plurality of other ECUs, in which the first ECU includes a processor configured to determine a security state based on at least information received from the sensor, and cause the alarm apparatus to operate when it is determined that the security state is abnormal.

Abstract: A pacifier 2 includes: a nipple portion 3 held in a mouth of the infant; and a back plate portion 4 that has an asymmetrical shape with respect to an axis 36 passing through a center 35 of the nipple portion 3 and extending in a vertical direction connecting a nose and the mouth of the infant in a state where the infant holds the pacifier 2 in the mouth. The back plate portion 4 includes: a main body portion 41; and an extension portion 42 that is connected to the main body portion 41 on either side of a lateral direction that is perpendicular to the vertical direction and connects left and right cheeks of the infant in a state where the infant holds the pacifier 2 in the mouth, the extension portion 42 extending from the main body portion 41 toward the either side.

Abstract: An antenna device (10) for vehicle, includes a first antenna element (100) disposed on a ground (20), and a second antenna element (200) disposed on the ground (20), and at least a portion of the first antenna element (100) and at least a portion of the second antenna element (200) are capacitively coupled.

Abstract: According to one embodiment, a gas processing equipment includes an oxygen remover 2 that removes oxygen contained in exhaust gas G, and a gas processing device 3 that processes pretreated exhaust gas G (P), from which the oxygen has been removed by the oxygen remover 2, with a carbon dioxide absorbent solvent S as a treatment agent.

Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.

Abstract: An information processing apparatus, a system, and an information processing method.

Abstract: A porous metal organic framework having gas adsorption selectivity and excellent water resistance, an adsorbent consisting of the porous metal organic framework, and a method for separating carbon dioxide using the same are provided, which are: a porous metal organic framework, which is characterized by comprising a metal oxalate, a cycloazocarbyl compound, and a bidentate organic ligand; an adsorbent consisting of the porous metal organic framework; and a method for separating carbon dioxide using the same.

Abstract: An information processing apparatus, a system, and an information processing method.

Abstract: The present disclosure provides a method of preventing or delaying the progression from mild cognitive impairment (MCI) to dementia or a therapeutic agent therefor.

Abstract: An image reading device and an image forming apparatus. The image reading device includes an image reader to read an image of a document, and a color reference component arranged to face the image reader. In the image reading device, the image reader reads the color reference component at a prescribed timing to obtain color reference image data, and correction data generating processes are executed based on the obtained color reference image data to generate correction data used to correct data of the image read by the image reader. In the image reading device, wherein the color reference component is moved relative to the image reader in a direction orthogonal to a direction toward and away from the image reader. The image forming apparatus includes the image reading device, and an image is formed on a recording material based on data of the image read by the image reading device.

Abstract: According to one embodiment, a gas processing equipment includes an oxygen remover 2 that removes oxygen contained in exhaust gas G, and a gas processing device 3 that processes pretreated exhaust gas G (P), from which the oxygen has been removed by the oxygen remover 2, with a carbon dioxide absorbent solvent S as a treatment agent.

Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.

Abstract: A carbon dioxide capture system according to an embodiment includes: a carbon dioxide capturer, an absorbing liquid regenerator, a first washer, a second washer, and an absorbing liquid line. The first washer washes the combustion exhaust gas discharged from the carbon dioxide capturer with a mist of a first cleaning liquid sprayed by a first spray to capture the amine accompanying the combustion exhaust gas. The absorbing liquid line supplies the absorbing liquid regenerated in the absorbing liquid regenerator as the first cleaning liquid to the first spray. The first cleaning liquid sprayed by the first spray is supplied as the absorbing liquid to the carbon dioxide capturer.